Your shopping cart is empty

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

Check out our free and informative ezines and sign up now

Home > Newsletters > Drug Industry Daily > Impax Can Launch Generic Renvela, Renagel in 2014 Following Genzyme Settlement

Drug Industry Daily

Sept. 5, 2012 | Vol. 11 No. 174

Impax Can Launch Generic Renvela, Renagel in 2014 Following Genzyme Settlement

Impax Laboratories can market generic versions of Genzyme’s kidney disease drugs Renvela and Renagel in 2014 under a settlement with the brand drugmaker.

This article is viewable by subscribers only. To view this article, please select an option below.

Subscribe
Print This Page
Email This Article
RSS
Free Trial
Archives
Sample PDF

Briefs Perrigo Can Launch Ofirmev Generic in 2020, May Get Authorized Generic Deal Perrigo Can Launch Ofirmev Generic in 2020, May Get Authorized Generic Deal Abbott Hits Watson With Second Suit Against Expanded Niaspan ANDA

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.